Home / Business and Economy / Eli Lilly Surges: Q1 Fuels Upbeat 2026 Outlook
Eli Lilly Surges: Q1 Fuels Upbeat 2026 Outlook
30 Apr
Summary
- Eli Lilly raised its full-year 2026 guidance.
- First quarter revenues significantly boosted performance.
- Company stock saw a notable increase in pre-market trading.
In its first quarter financial results reported on Thursday, Eli Lilly and Co. significantly improved its earnings and revenue outlook for the entirety of 2026. The drugmaker's updated guidance reflects a robust revenue performance achieved during the initial quarter of the fiscal year.
Eli Lilly now projects its full-year 2026 earnings to fall between $35.50 and $37.00 per share, with revenues estimated to be between $82 billion and $85 billion. This revised forecast represents an increase from the company's prior expectations of earnings ranging from $33.50 to $35.00 per share and revenues between $80.0 billion and $83.0 billion.
Following the announcement, Eli Lilly's stock experienced a substantial surge. In pre-market trading on Thursday, the shares were up $45.29, representing a 5.32 percent increase, trading at $896.70 on the NYSE.
